食管癌免疫治疗研究进展  

Research Progress on Immunotherapy for Esophageal Cancer

作　　者：杨帅[1] 许瑞彬[2] 

机构地区：[1]延安大学,第一临床医学院,陕西 延安 [2]延安大学附属医院,胸外科,陕西 延安

出　　处：《临床医学进展》2022年第7期6922-6928,共7页Advances in Clinical Medicine

摘　　要：食管癌(Esophageal cancer, EC)是一种具有高度侵袭性且预后较差的恶性肿瘤,食管癌的发病率和死亡率均处于较高水平,严重威胁人类健康,目前,食管癌的标准治疗方案包括手术、放疗和化疗,尽管使用了多学科疗法,食管癌患者的预后仍不理想,5年总生存率仅为30%~40%,且目前尚无针对食管癌的特异性靶向药应用于临床。作为一种新的有效的癌症治疗手段,免疫治疗在食管癌治疗中具有广阔的应用前景。许多II、III期临床试验证实免疫治疗联合放化疗可以增强抗肿瘤作用。本文就目前免疫治疗在晚期食管癌中的临床研究展开论述。Esophageal cancer (EC) is a highly invasive malignant tumor with poor prognosis. The incidence and mortality of esophageal cancer are both at a high level, posing a serious threat to human health. Currently, the standard treatment plan for esophageal cancer includes surgery, radiotherapy and chemotherapy. Despite the use of multidisciplinary therapies, the prognosis of patients with esophageal cancer is still not ideal, the 5-year overall survival rate is only 30%~40%, and there is no specific targeted drug for esophageal cancer applied in clinic. As a new effective cancer treat-ment, immunotherapy has a broad application prospect in the treatment of esophageal cancer. Many phase II and III clinical trials have demonstrated that immunotherapy combined with chemoradiotherapy can enhance the antitumor effect. This article discusses the clinical study of immunotherapy in esophageal cancer.

关 键 词：食管癌 免疫治疗 联合治疗 

分 类 号：R735.1[医药卫生—肿瘤] R730.51[医药卫生—临床医学]